Lesson
Use Structure to Explain Early Cell-Wall Arrest
Fosfomycin is a small phosphonic acid derivative delivered orally as a tromethamine salt. Its strained epoxide reacts with an active-site cysteine in MurA, irreversibly blocking an early committed step in peptidoglycan precursor synthesis.
- Phosphonic acid
- Epoxide
- MurA
- UDP-N-acetylglucosamine
- Peptidoglycan
The tromethamine salt carries a compact polar active moiety.
Nutrient transport systems provide target access.
The strained epoxide forms a covalent adduct.
An early committed cell-wall step is blocked.
Name the direct target
Fosfomycin inactivates enolpyruvyl transferase, commonly called MurA. It does not bind a penicillin-binding protein, ribosome, DNA gyrase, or RNA polymerase.
Place the step correctly
MurA catalyzes condensation of UDP-N-acetylglucosamine with phosphoenolpyruvate. This cytoplasmic precursor step occurs earlier than the membrane and extracellular steps targeted by several other cell-wall agents.
Connect the epoxide to irreversible inhibition
The strained epoxide is electrophilic. An active-site cysteine attacks it and forms a covalent adduct, which explains irreversible target inactivation.
Separate salt mass from active moiety
The oral product contains the tromethamine salt to support delivery. Free fosfomycin is the antibacterial moiety after absorption.
Quick check
Checking for saved practice…
Lesson
Make Target Access Part of the Mechanism
Fosfomycin must cross the bacterial membrane through nutrient transport systems before it can reach cytosolic MurA. Reduced uptake, target change, and enzymatic inactivation can each break the pathway from extracellular drug to antibacterial effect.
- Transport
- Intracellular exposure
- Reduced uptake
- fosA
- Species
Reduced uptake lowers intracellular fosfomycin.
Active drug must remain chemically intact.
Glutathione addition can destroy target binding.
E. coli guidance does not transfer to Klebsiella.
Uptake is required
High urine concentration does not bypass the bacterial membrane. Reduced expression or function of transport pathways can lower intracellular exposure and produce resistance.
FosA destroys active drug
FosA enzymes use glutathione to open and modify the epoxide, preventing productive MurA binding. The 2026 IDSA guidance highlights the high prevalence of fosA in organisms such as Klebsiella pneumoniae.
Species identity changes the answer
Oral fosfomycin guidance for resistant gram-negative cystitis is limited to E. coli. Do not generalize that recommendation to every Enterobacterales isolate.
Distinct mechanism is not universal susceptibility
Fosfomycin usually lacks cross-resistance with beta-lactams and aminoglycosides. That advantage still requires supported testing, organism-level interpretation, and a matching infection site.
Quick check
Checking for saved practice…
Lesson
Keep the Infection Inside the Bladder
The oral sachet is labeled only for uncomplicated acute cystitis in adult women. Fever, flank pain, systemic illness, obstruction, renal parenchymal involvement, abscess, or bacteremia changes the compartment and the treatment pathway.
- Dysuria
- Lower tract
- Pyelonephritis
- Perinephric abscess
- Bacteriuria
Dysuria, frequency, and urgency support cystitis.
Upper-tract disease needs another regimen.
Anatomy, obstruction, pregnancy, and severity matter.
Culture and choose another agent after failure.
Symptoms establish the syndrome
Dysuria, frequency, and urgency support cystitis. A positive culture without symptoms is bacteriuria, which has different treatment rules and should not trigger automatic fosfomycin use.
Fever or flank pain changes the compartment
The oral label specifically excludes pyelonephritis and perinephric abscess. High urine concentration does not prove adequate renal parenchymal or bloodstream exposure.
Host context still matters
Pregnancy, urinary obstruction, structural abnormality, immunocompromise, severe illness, recurrent infection, and recent resistant isolates may require a different evaluation or regimen.
Persistence is not a refill signal
If bacteriuria persists or reappears, reassess diagnosis, culture, susceptibility, adherence, anatomy, and upper-tract features, then select another therapeutic agent.
Quick check
Checking for saved practice…
Lesson
Separate Label Evidence from In Vitro Possibility
The oral label establishes acute cystitis treatment for susceptible E. coli and Enterococcus faecalis. Current resistance guidance adds a narrower alternative role for ESBL-producing E. coli and warns against extending that role to other gram-negative species.
- E. coli
- E. faecalis
- ESBL
- Klebsiella
- Susceptibility testing
Susceptible strains support the oral indication.
Oral fosfomycin is an alternative for uUTI.
Frequent fosA carriage compromises transfer.
A missing susceptibility result is missing evidence.
Use the labeled pair
Susceptible E. coli and E. faecalis are the organisms supported by the oral indication. The label lists broader in vitro activity separately and states that clinical significance is unknown.
Treat ESBL E. coli as an alternative role
The 2026 IDSA guidance lists oral fosfomycin as an alternative for uncomplicated UTI caused by ESBL-producing E. coli. Preferred active options should still be considered first.
Do not transfer the recommendation to Klebsiella
Klebsiella pneumoniae commonly carries fosA. The same resistance mechanism can undermine activity even when a broad in vitro list appears reassuring.
Know the testing limitation
Many laboratories do not routinely report fosfomycin susceptibility. A missing result is missing evidence, not an implied susceptible result. Species and breakpoint context matter.
Quick check
Checking for saved practice…
Lesson
Make One Sachet One Complete Course
One single-dose sachet contains 5.631 grams of fosfomycin tromethamine, equivalent to 3 grams of active fosfomycin. The entire packet is dissolved in 3 to 4 ounces of nonhot water and taken immediately.
- One sachet
- 3 grams active
- 5.631 grams salt
- 3 to 4 ounces
- No hot water
The packet contains the tromethamine compound.
Counterion mass does not increase active fosfomycin.
Use nonhot water and the entire sachet.
Drink once after the granules dissolve.
Calculate the active amount correctly
The full sachet contains 5.631 grams of the tromethamine salt but only 3 grams of active fosfomycin. Counterion mass explains the difference.
Do not swallow dry granules
Empty the full packet into 3 to 4 ounces of water, stir to dissolve, and take it immediately. The product is not designed to be swallowed directly from the sachet.
Keep heat out of preparation
The label specifically says not to use hot water. Room-temperature or cold water supports a simple, reproducible teach-back.
Do not prescribe routine daily repetition
One sachet is one labeled course. Repeated daily doses did not improve clinical success or eradication in the label and increased adverse events.
Quick check
Checking for saved practice…
Lesson
Match Exposure to the Urinary Compartment
Oral fosfomycin tromethamine is rapidly absorbed and converted to free fosfomycin. Bioavailability is modest, protein binding is absent, elimination is unchanged in urine and feces, and urinary concentration persists longer than the serum peak.
- Bioavailability
- No protein binding
- Urinary excretion
- Food
- Renal impairment
Food changes rate but not the labeled administration rule.
Fosfomycin is not plasma protein bound.
High urinary exposure supports the cystitis role.
Half-life rises while urinary recovery falls.
Food changes rate more than the labeled decision
Bioavailability falls from about 37% fasting to 30% fed and the urinary peak is delayed. Cumulative urinary recovery and the stated duration above 100 mcg/mL were similar, so administration may be with or without food.
Urine is the useful compartment
Mean fasting urine concentration reached about 706 mcg/mL within 2 to 4 hours and remained measurable for days. This supports bladder treatment, not a claim of reliable systemic or renal tissue therapy.
The active drug is eliminated unchanged
About 38% of the oral dose was recovered in urine and 18% in feces. Fosfomycin does not rely on conversion to an active metabolite.
Renal impairment changes both sides of exposure
As creatinine clearance fell from 54 to 7 mL/min, half-life rose from about 11 to 50 hours and urinary recovery fell from 32% to 11%. Longer systemic persistence does not guarantee better urinary treatment.
Quick check
Checking for saved practice…
Lesson
Balance Convenience Against Comparative Effectiveness
Single-dose administration can improve execution, but convenience does not make oral fosfomycin the most effective option. Current guidance and clinical data place it behind preferred active agents for resistant E. coli cystitis.
- Alternative oral role
- Nitrofurantoin
- Treatment success
- Multidose uncertainty
- Intravenous product
Keep infection confined to the bladder.
Use current guidance and patient context.
Reserve for a supported E. coli scenario.
Evidence remains limited outside the narrow role.
Use current oral placement
For ESBL-producing E. coli uncomplicated UTI, 2026 IDSA guidance lists several preferred options and oral fosfomycin as an alternative. Availability, susceptibility, safety, prior cultures, and patient priorities shape the choice.
Discuss the comparative trial
The current guidance cites treatment success of 70% with five-day nitrofurantoin and 58% with single-dose fosfomycin among E. coli uncomplicated UTI. Fewer doses did not produce better outcomes.
Keep multidose oral therapy evidence-limited
The clinical benefit of extra oral doses remains uncertain. The oral label warns that repeated daily dosing did not improve success and increased adverse events, while the 2025 IDSA cUTI guideline considers oral fosfomycin generally inappropriate because tissue and bloodstream exposure are inadequate.
Separate the new intravenous product
CONTEPO is FDA approved for adults with complicated UTI, including acute pyelonephritis, caused by susceptible E. coli or Klebsiella pneumoniae. Its intravenous formulation, 6 gram vial, regimen, renal adjustment, laboratory monitoring, QT precautions, and other safety requirements cannot be transferred to the oral sachet.
Quick check
Checking for saved practice…
Lesson
Prioritize the Safety Signals That Change Care
Most patients encounter gastrointestinal or neurologic tolerability issues, but hypersensitivity, delayed antibiotic-associated diarrhea, and reduced exposure from gastrointestinal motility drugs require explicit action plans.
- Hypersensitivity
- Diarrhea
- Vaginitis
- CDAD
- Metoclopramide
Diarrhea, nausea, and dyspepsia can occur.
Anaphylaxis and angioedema need urgent care.
CDAD can emerge well after the dose.
Faster motility can reduce urinary exposure.
Hypersensitivity is the contraindication
Known fosfomycin hypersensitivity excludes use. Postmarketing reports include anaphylaxis and angioedema, which require urgent assessment and treatment.
Prioritize common effects
Drug-related trial events above 1% included diarrhea, vaginitis, nausea, headache, dizziness, asthenia, and dyspepsia. Counseling should make these recognizable without burying them under rare events.
Keep CDAD in the timeline
Clinically important watery or bloody diarrhea, fever, or abdominal pain can emerge during therapy or more than two months later. Evaluate rather than reflexively suppressing symptoms.
Motility can reduce exposure
Metoclopramide and other drugs that increase gastrointestinal motility can lower serum concentration and urinary excretion of fosfomycin. Reconcile these agents before treatment.
Quick check
Checking for saved practice…
Lesson
Use Current Population Narratives Instead of Shortcuts
Pregnancy, lactation, pediatric age, geriatric complexity, and renal impairment require evidence-based narrative decisions. Retired pregnancy letters and age-only rules cannot capture the relevant uncertainty.
- Placental transfer
- Human evidence gap
- Lactation
- Pediatrics
- Kidney function
Placental transfer and limited human data shape risk.
Milk exposure evidence is not established.
The labeled regimen is for adult women.
Renal decline changes half-life and urinary recovery.
Pregnancy needs a current narrative
Fosfomycin crosses the placenta. Adequate controlled studies in pregnant women are lacking, while animal findings varied by species and maternal toxicity. Use indication-specific benefit-risk reasoning rather than a retired category.
Lactation evidence remains incomplete
The label does not establish whether fosfomycin tromethamine enters human milk. Balance maternal need, infant context, alternatives, feeding goals, and a practical monitoring plan.
Separate pediatric boundaries
Safety and effectiveness are not established in children 12 years and younger. The labeled acute cystitis regimen itself is for women 18 years and older, so adolescents require diagnosis-specific review rather than automatic adult extrapolation.
Older age does not erase complexity
Limited data did not identify an age-only urinary excretion difference, but older adults often have reduced kidney function, structural disease, interacting drugs, atypical symptoms, and a higher chance that the infection is not uncomplicated.
Quick check
Checking for saved practice…
Lesson
Close the Fosfomycin Loop
A safe plan makes the diagnosis, infection compartment, organism, resistance biology, exact product, preparation, exposure, evidence, safety, response, and exit criteria agree before the sachet is opened.
- Phenotype
- Organism
- Product
- Exposure
- Follow-up
Exclude upper-tract and systemic disease.
Use species-specific current guidance.
Prepare the full packet correctly.
Reassess nonresponse rather than repeating automatically.
Start with the compartment
Confirm symptomatic infection confined to the bladder. Fever, flank pain, obstruction, abscess, bacteremia, or systemic instability requires another pathway.
Make microbiology specific
Use the label for susceptible E. coli or E. faecalis and current guidance for the alternative ESBL E. coli role. Do not transfer the recommendation to Klebsiella or infer susceptibility from a missing result.
Execute one complete course
Dispense one sachet, explain that 5.631 grams of salt equals 3 grams of active fosfomycin, mix the full packet in 3 to 4 ounces of nonhot water, and drink immediately.
Define what happens next
Symptoms should begin improving within two to three days. New fever, flank pain, severe reaction, significant diarrhea, or persistence requires prompt reassessment rather than automatic repeated doses.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 168 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- DailyMed. Fosfomycin tromethamine granules for oral solution prescribing information.
- DailyMed. CONTEPO intravenous fosfomycin prescribing information.
- FDA. Fosfomycin injection susceptibility interpretive criteria.
- IDSA. 2026 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.
- IDSA. 2025 guideline for complicated urinary tract infections.